Platinib and seputinib: An analysis of the similarities and differences between the two RET inhibitors

Pralsetinib and Selpercatinib are both oral, highly selective RET inhibitors approved by the U.S. Food and Drug Administration (FDA). They have emerged in the treatment of cancer targeting RET gene mutations. However, although they all belong to the same class of drugs, they have shown their own uniqueness in indications, mechanisms of action and certain clinical manifestations.

Platinib, as an innovative drug targeting RET gene mutations, is widely used in the treatment of non-small cell lung cancer (NSCLC) and thyroid cancer. This drug effectively blocks the growth and survival signals of cancer cells by precisely inhibiting multiple mutant or rearranged RET protein kinases. In multiple clinical trials, platinib has demonstrated excellent anti-tumor activity, bringing new hope to patients with NSCLC and thyroid cancer.

Seputinib, also aRET inhibitor, has also been approved by the FDA for the treatment of adult patients with RET gene mutations, including thyroid cancer, non-small cell lung cancer (NSCLC) and anaplastic thyroid cancer. The mechanism of action of seputinib is similar to that of platinib, both of which exert anti-tumor effects by inhibiting the activity of RET protein kinase. In clinical trials, seputinib also showed satisfactory efficacy, providing more treatment options for cancer patients.

It is worth mentioning that both drugs have shown therapeutic potential for brain metastases, and their drug metabolism is mainly carried out through the liver'sCYP3A4 enzyme. However, they differ when it comes to adverse effects. Common grade 3 or 4 adverse reactions of seputinib include hypertension, increased ALT levels, and increased AST levels; while platinib is more likely to cause neutropenia, hypertension, and anemia. In addition, patients taking seputinib need to pay additional attention to the risk of QT prolongation; while patients taking platinib need to pay attention to the risk of interstitial lung disease or pneumonia.